1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
4.2.2 Rising Investments in Research and Development of Novel Drugs
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Instability of Peptides
4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval?
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Marketing type
5.1.1 Generic
5.1.2 Branded
5.2 By Application
5.2.1 Gastrointestinal Disorders
5.2.2 Neurological Disorders
5.2.3 Metabolic Disorders
5.2.4 Cancer
5.2.5 Other Applications
5.3 By Route of Administration
5.3.1 Parenteral
5.3.2 Oral
5.3.3 Other Routes of Administration
5.4 Geography
5.4.1 North America
5.4.1.1 United States (By Marketing Type, By Application, and By Route of Administration)
5.4.1.2 Canada (By Marketing Type, By Application, and By Route of Administration)
5.4.1.3 Mexico (By Marketing Type, By Application, and By Route of Administration)
5.4.2 Europe
5.4.2.1 Germany (By Marketing Type, By Application, and By Route of Administration)
5.4.2.2 United Kingdom (By Marketing Type, By Application, and By Route of Administration)
5.4.2.3 France (By Marketing Type, By Application, and By Route of Administration)
5.4.2.4 Italy (By Marketing Type, By Application, and By Route of Administration)
5.4.2.5 Spain (By Marketing Type, By Application, and By Route of Administration)
5.4.2.6 Rest of Europe (By Marketing Type, By Application, and By Route of Administration)
5.4.3 Asia-Pacific
5.4.3.1 China (By Marketing Type, By Application, and By Route of Administration)
5.4.3.2 Japan (By Marketing Type, By Application, and By Route of Administration)
5.4.3.3 India (By Marketing Type, By Application, and By Route of Administration)
5.4.3.4 Australia (By Marketing Type, By Application, and By Route of Administration)
5.4.3.5 South Korea (By Marketing Type, By Application, and By Route of Administration)
5.4.3.6 Rest of Asia-Pacific (By Marketing Type, By Application, and By Route of Administration)
5.4.4 Middle East and Africa
5.4.4.1 GCC (By Marketing Type, By Application, and By Route of Administration)
5.4.4.2 South Africa (By Marketing Type, By Application, and By Route of Administration)
5.4.4.3 Rest of Middle East and Africa (By Marketing Type, By Application, and By Route of Administration)
5.4.5 South America
5.4.5.1 Brazil (By Marketing Type, By Application, and By Route of Administration)
5.4.5.2 Argentina (By Marketing Type, By Application, and By Route of Administration)
5.4.5.3 Rest of South America (By Marketing Type, By Application, and By Route of Administration)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Amgen, Inc.
6.1.3 Pfizer, Inc.
6.1.4 Bristol-Myers Squibb Company
6.1.5 Ever Neuro Pharma GmbH
6.1.6 Takeda Pharmaceutical Company Limited
6.1.7 Teva Pharmaceuticals Industries Ltd
6.1.8 AstraZeneca PLC
6.1.9 GlaxoSmithKline plc
6.1.10 Novo Nordisk A/S.
6.1.11 Novartis AG
6.1.12 Zealand Pharma AG
6.1.13 AmbioPharm Inc.
6.1.14 Bachem Holding AG
6.1.15 PolyPeptide Group
6.1.16 Sanofi SA
6.1.17 Amylin Pharmaceuticals
6.1.18 CirclePharma, Inc
6.1.19 PeptiDream Inc
6.1.20 Apitope Technology
6.1.21 Arch NioPartners
6.1.22 Galena Biopharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Eli Lilly and Company
- Amgen, Inc.
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- Ever Neuro Pharma GmbH
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd
- AstraZeneca PLC
- GlaxoSmithKline plc
- Novo Nordisk A/S.
- Novartis AG
- Zealand Pharma AG
- AmbioPharm Inc.
- Bachem Holding AG
- PolyPeptide Group
- Sanofi SA
- Amylin Pharmaceuticals
- CirclePharma, Inc
- PeptiDream Inc
- Apitope Technology
- Arch NioPartners
- Galena Biopharmaceuticals